These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 17993633

  • 1. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
    Mego M, Reckova M, Obertova J, Sycova-Mila Z, Brozmanova K, Mardiak J.
    Ann Oncol; 2007 Nov; 18(11):1906-7. PubMed ID: 17993633
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
    Strumberg D.
    J Clin Oncol; 2008 Jul 10; 26(20):3469-71; author reply 2471. PubMed ID: 18612169
    [No Abstract] [Full Text] [Related]

  • 3. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
    Loriot Y, Boudou-Rouquette P, Billemont B, Ropert S, Goldwasser F.
    Ann Oncol; 2008 Nov 10; 19(11):1975. PubMed ID: 18723549
    [No Abstract] [Full Text] [Related]

  • 4. Kidney cancer: Does hypothyroidism predict clinical outcome?
    Rini B.
    Nat Rev Urol; 2011 Jan 10; 8(1):10-1. PubMed ID: 21116300
    [No Abstract] [Full Text] [Related]

  • 5. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Ravaud A, Sire M.
    Ann Oncol; 2009 May 10; 20(5):966-7; author reply 967. PubMed ID: 19403939
    [No Abstract] [Full Text] [Related]

  • 6. [Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
    Staehler M, Haseke N, Schöppler G, Stadler T, Heinemann G, Stief CG.
    Urologe A; 2006 Oct 10; 45(10):1333-42; quiz 1343. PubMed ID: 17021905
    [Abstract] [Full Text] [Related]

  • 7. Therapy for metastatic RCC--questions remain.
    Breau RH, Leibovich BC.
    Nat Rev Urol; 2009 Nov 10; 6(11):580-1. PubMed ID: 19890336
    [No Abstract] [Full Text] [Related]

  • 8. Two new drugs for renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Feb 26; 49(1255):18-20. PubMed ID: 17325624
    [No Abstract] [Full Text] [Related]

  • 9. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
    Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H.
    J Clin Oncol; 2008 Nov 10; 26(32):5204-12. PubMed ID: 18838713
    [Abstract] [Full Text] [Related]

  • 10. [New therapeutic regimes in metastasic renal-cell carcinoma].
    Bierer S, Hertle L, Nitschmann S.
    Internist (Berl); 2008 Jan 10; 49(1):114-7. PubMed ID: 18704353
    [No Abstract] [Full Text] [Related]

  • 11. Sorafenib and sunitinib.
    Kim A, Balis FM, Widemann BC.
    Oncologist; 2009 Aug 10; 14(8):800-5. PubMed ID: 19648603
    [No Abstract] [Full Text] [Related]

  • 12. [New drugs; sunitinib and sorafenib].
    van Bronswijk H, Dubois EA, Osanto S, Cohen AF.
    Ned Tijdschr Geneeskd; 2007 Dec 29; 151(52):2888-90. PubMed ID: 18257434
    [Abstract] [Full Text] [Related]

  • 13. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
    Grandinetti CA, Goldspiel BR.
    Pharmacotherapy; 2007 Aug 29; 27(8):1125-44. PubMed ID: 17655513
    [Abstract] [Full Text] [Related]

  • 14. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, Clodi M, Kramer G, Zielinski CC.
    Cancer; 2011 Feb 01; 117(3):534-44. PubMed ID: 20845482
    [Abstract] [Full Text] [Related]

  • 15. Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.
    Feinberg BA, Jolly P, Wang ST, Fortner B, Scott J, Gilmore J, Neary MP, Duh MS.
    Med Oncol; 2012 Jun 01; 29(2):786-94. PubMed ID: 21479699
    [Abstract] [Full Text] [Related]

  • 16. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
    Bukowski RM.
    Clin Genitourin Cancer; 2009 Jan 01; 7(1):9-10. PubMed ID: 19213661
    [No Abstract] [Full Text] [Related]

  • 17. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.
    Herrmann E, Marschner N, Grimm MO, Ohlmann CH, Hutzschenreuter U, Overkamp F, Groschek M, Blumenstengel K, Pühse G, Steiner T.
    World J Urol; 2011 Jun 01; 29(3):361-6. PubMed ID: 21461939
    [Abstract] [Full Text] [Related]

  • 18. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib.
    Overkleeft EN, Goldschmeding R, van Reekum F, Voest EE, Verheul HM.
    Ann Oncol; 2010 Jan 01; 21(1):184-5. PubMed ID: 19889617
    [No Abstract] [Full Text] [Related]

  • 19. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
    Kitajima K, Takahashi S, Maeda T, Yoshikawa T, Ohno Y, Fujii M, Miyake H, Fujisawa M, Sugimura K.
    Eur J Radiol; 2012 Sep 01; 81(9):2060-5. PubMed ID: 21724350
    [Abstract] [Full Text] [Related]

  • 20. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.
    Am J Clin Oncol; 2010 Jun 01; 33(3):217-20. PubMed ID: 19745694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.